Summit Financial Strategies 13F: Exits CVS Health (CVS) Stake

Summit Financial Strategies sold its entire stake in CVS Health Corporation CVS, unloading all 2,057 shares according to a Form 13F filing with the Securities and Exchange Commission on October 14, 2026. Because 13F filings look backward at holdings from the end of the quarter, this disclosure reflects portfolio choices made earlier and may not show where the fund stands today.

Inside Summit Financial Strategies's CVS Health Trade

The fund completely parted ways with its CVS Health shares, dropping its position from 2,057 shares down to zero. The reported value of the holding prior to the exit was tied to the portfolio's prior positioning during the period.

Other Institutional Activity in CVS Health

Blackrock Inc. trimmed its holdings by 2,694,646 shares, ending with 123,223,409 shares worth about $11.38 billion. Vanguard Capital Management LLC grew its holdings by 661,233 shares, ending with 83,315,369 shares worth about $7.70 billion. Capital World Investors reduced its stake by 2,294,211 shares, leaving it with 74,951,955 shares valued at roughly $6.92 billion. State Street Corporation lifted its position by 961,023 shares to finish with 60,283,408 shares worth about $5.57 billion. Dodge & Cox Inc. pared back its stake by 1,765,644 shares, closing the period with 50,012,765 shares valued at about $4.62 billion.

CVS Health Corporation Stock Up 2.7%

CVS Health shares recently traded around $92.83 as of October 16, 2026. The stock trades above its 50-day moving average of $91.80 and above its 200-day moving average of $88.12. Over the past year, shares have moved between a 52-week low of $69.51 and a 52-week high of $110.68.

Recent Earnings

CVS Health reported trailing-twelve-month revenue of $412.65 billion alongside earnings of $3.80 per share. The company posts a net profit margin of 1.2% and a return on equity of 6.2%, with its next earnings report scheduled for November 4, 2026.

Dividend

The company distributes an annual dividend yielding 2.87% supported by a payout ratio of 70.0%.

Insider Buying and Selling at CVS Health Corporation

Company insiders executed notable transactions earlier in the year, including open-market sales by officers and directors prior to the filing date.

Analysts Set New Price Targets

Wall Street firms continue to update their views on the stock, with analysts maintaining a strong buy consensus and an average price target of $115.48 across 25 analyst opinions.

About CVS Health Corporation

CVS Health Corporation operates as a major healthcare provider in the United States, offering pharmacy benefits, health insurance plans, and retail pharmacy services through its extensive network. The company connects patients with medical management, prescription drug coverage, and clinical services. Institutional portfolio changes surrounding the stock arrive as management continues to navigate shifts across the healthcare sector.

Bottom Line

Keep in mind that 13F filings offer a retrospective look at institutional portfolios and might not match a fund's current holdings. Observers will look toward the company's upcoming earnings release on November 4, 2026, for further financial updates. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.